Nifty 17469.75 (1.71%)
Sensex 58649.68 (1.76%)
Nifty Bank 37284.7 (1.82%)
Nifty IT 35959.05 (1.95%)
Nifty Financial Services 18284.95 (1.70%)
Adani Ports 761.40 (2.24%)
Asian Paints 3108.50 (2.58%)
Axis Bank 697.10 (1.47%)
B P C L 391.15 (0.86%)
Bajaj Auto 3332.05 (1.39%)
Bajaj Finance 7361.50 (3.64%)
Bajaj Finserv 17621.65 (3.00%)
Bharti Airtel 715.15 (2.33%)
Britannia Inds. 3575.75 (2.92%)
Cipla 897.95 (0.98%)
Coal India 150.90 (0.17%)
Divis Lab. 4604.95 (-0.43%)
Dr Reddys Labs 4570.70 (1.11%)
Eicher Motors 2505.55 (1.37%)
Grasim Inds 1716.25 (1.82%)
H D F C 2853.00 (1.26%)
HCL Technologies 1171.60 (1.91%)
HDFC Bank 1553.80 (1.84%)
HDFC Life Insur. 686.40 (-1.15%)
Hero Motocorp 2490.65 (1.17%)
Hind. Unilever 2340.60 (0.82%)
Hindalco Inds. 457.45 (3.38%)
I O C L 120.40 (-0.17%)
ICICI Bank 753.40 (2.55%)
IndusInd Bank 945.30 (2.01%)
Infosys 1753.35 (2.44%)
ITC 224.95 (1.95%)
JSW Steel 672.95 (1.86%)
Kotak Mah. Bank 1920.45 (-0.86%)
Larsen & Toubro 1825.05 (1.50%)
M & M 840.75 (1.79%)
Maruti Suzuki 7434.90 (3.46%)
Nestle India 19479.10 (0.70%)
NTPC 127.25 (1.52%)
O N G C 148.40 (1.71%)
Power Grid Corpn 204.80 (-0.49%)
Reliance Industr 2418.10 (1.52%)
SBI Life Insuran 1169.50 (0.89%)
Shree Cement 26106.90 (1.40%)
St Bk of India 491.55 (3.12%)
Sun Pharma.Inds. 757.55 (1.86%)
Tata Consumer 772.15 (1.51%)
Tata Motors 493.90 (2.51%)
Tata Steel 1173.00 (2.11%)
TCS 3626.90 (1.18%)
Tech Mahindra 1604.80 (1.79%)
Titan Company 2405.55 (1.05%)
UltraTech Cem. 7423.95 (1.71%)
UPL 728.10 (0.16%)
Wipro 641.70 (1.47%)
SUVEN

Suven Life Sciences Ltd.

₹92.
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

  • Master Rating:
  • Suven Life Sciences has an operating revenue of Rs. 6.26 Cr. on a trailing 12-month basis. An annual revenue de-growth of -25% needs improvement, Pre-tax margin of -575% needs improvement, ROE of -66% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 2 which is a POOR score indicating inconsistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 147 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Analyst Recommendation : HOLD

Suven Life Sciences Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Suven Life Sciences Ltd Synopsis

NSE-Medical-Diversified

Suven Life Sciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 13.48 Cr. and Equity Capital is Rs. 12.73 Cr. for the Year ended 31/03/2021. Suven Life Sciences Ltd. is a Public Limited Listed company incorporated on 09/03/1989 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1989PLC009713 and registration number is 009713.
  • Market Cap

    INR 1,174.19 Cr

  • Sales

    INR 6.26 Cr

  • Shares in Float

    5.09 Cr

  • No of Funds

    15 K

  • Yield

    0.89%

  • Book Value

    2.84

  • U/D Vol Ratio

    2

  • LTDebt/Equity

    0%

  • Alpha

    -0.02

  • Beta

    1.2

Suven Life Sciences Ltd Ownership
Suven Life Sciences Ltd Management

Suven Life Sciences Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 401.6545387.6735401.7221866.6998731.5292
Fixed Assets Annual Cr 25.736624.693722.3683332.4694315.4404
Total Non Current Assets Annual Cr 320.7621357.7593158.7316451.8131388.982
Total Current Assets Annual Cr 94.623951.9976280.7555562.6633487.1875
Total Assets Annual Cr 415.386409.7569439.48711014.4764876.1695
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 31.556230.457831.561568.092857.4731
ROE Annual % -5.63-3.549.7518.2716.87
ROCE Annual % -6.68-6.3515.2826.1821.66
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % -169.11-147.2626.5840.9734.3

Suven Life Sciences Ltd Technicals

EMA & SMA

CURRENT PRICE

92 (2.62)

    • Bullish Moving Averages 7
    • Bearish Moving Averages 9

EMA

  • 20 Day

    93.63

  • 50 Day

    95.95

  • 100 Day

    94.61

  • 200 Day

    91.17

Suven Life Sciences Ltd Resistance and support

90.09 PIVOT

  • First Resistance

    90.97

  • Second Resistance

    92.29

  • Third Resistance

    93.17

  • First Support

    88.77

  • Second Support

    87.89

  • Third Support

    86.57

  • RSI

    44.91

  • MFI

    42.51

  • MACD

    -2.88

  • MACD signal line

    -2.79

Suven Life Sciences Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 301,582 12,307,561 40.81%
Week 205,892 10,051,657 48.82%
1 Month 350,096 16,307,465 46.58%
6 Month 899,733 38,445,585 42.73%

Suven Life Sciences Ltd Price change analysis

-8.95

Over 1 month

Low High
86.5 104.9

7.8

Over 3 month

Low High
81.6 124.45

-6.7

Over 6 months

Low High
73 124.45

18.25

Over Year

Low High
67.75 124.45

Similar Stocks

News

Suven Life Sci Consolidated September 2021 Net Sales at Rs 1

NULL Read More

Suven Life Sciences Ltd - 530239 - Announcement under Regula

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed t Read More

SUVEN LIFE SCIENCES LTD. - 530239 - Statement Of Deviation(S

With reference to the above subject, please find enclosed statement confirming that there were no deviation(s) or variation(s) in the use of Read More

Q2FY22 Result Quarterly Announced for Suven Life Sciences Lt

Highlights Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous Read More

SUVEN LIFE SCIENCES LTD. - 530239 - Un-Audited Standalone An

We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter Read More

Blogs

FAQs

Stock Directory-

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All 0-9